Regulatory legal regulation of the organization and financial provision of supportive therapy for oncological diseases and directions for its optimization

The potential benefits of supportive care offer patients more than many “palliative” methods of anti-tumor treatment. It should be regarded as a necessary part of comprehensive disease therapy rather than just an additional service. However, the imperfection of regulatory and organizational issues, including financial support, limits patients’ access to supportive therapy.

Aim. To analyze regulatory legal documents governing the organization and financial provision of supportive therapy for oncological diseases and identify areas for optimization.

Materials and methods. Content analysis and comparative legal analysis. The content analysis method was applied to 26 directly regulating various organizational aspects of medical care, including oncological diseases from 2012 to the present. In regulatory legal acts, the issues of organization and financing of supportive therapy for oncological diseases were specifically analyzed in terms of how well this area of medical care is regulated.

Results. The current fundamental regulatory legal acts governing the organization and financial provision of supportive therapy for oncological diseases and controlling the quality of the provided medical care contain almost no clear provisions that specify practical issues related to supportive therapy.

Conclusion. The absence of an officially established definition of “supportive therapy” within the Russian healthcare system and the lack of clear distinctions between the terms “medical rehabilitation” and “palliative care” lead to misunderstanding about the importance of this area in comprehensive oncological therapy. This results in uncertainty in organizational and financial matters. To optimize regulatory oversight, ‘supportive therapy’ should become an integral component of modern oncological disease management, implying both interdisciplinary cooperation and a transparent financial system, the adequacy of which will depend on what is included in this concept.

1. Renke A.L., Zhezher A.A., Shlapak I.P. Supporting treatment of chemotherapy complications in oncological patients. Emergency medicine. 2015; 1(64): 20–26 (In Russian). EDN: TZFKWX

2. Berman R., Davies A., Cooksley T., et al. Supportive Care: An Indispensable Component of Modern Oncology. Clinical oncology (Royal College of Radiologists (Great Britain)). 2020; 32(11): 781–788. https://doi.org/10.1016/j.clon.2020.07.020

3. Tamang R., Bharati L., Khatiwada A.P., et al. Pattern of Adverse Drug Reactions Associated with the Use of Anticancer Drugs in an Oncology-Based Hospital of Nepal. JMA journal. 2022; 5(4): 416–426. https://doi.org/10.31662/jmaj.2021-0015

4. Sullivan R., Peppercorn J., Sikora K., et al. Delivering affordable cancer care in high-income countries. The Lancet. Oncology. 2011; 12(10): 933–980. https://doi.org/10.1016/S1470-2045(11)70141-3

5. Niezova Sh.Kh. Modern opportunities for correction of hepatotoxic syndrome for poly chemotherapy of solid tumors (literature review). European science. 2019; 5(47): 73–79 (In Russian). https://doi.org/10.24411/2410-2865-2019-10505. EDN: XQGQGJ

6. Kolodziej M.A. Alternative approaches to paying for cancer care. Oncology (Williston Park). 2011; 25(2): 108, 110, 113. PMID: 21456381

7. Jordan K., Aapro M., Kaasa S., et al. European Society for Medical Oncology (ESMO) position paper on supportive and palliative care. Annals of oncology: official journal of the European Society for Medical Oncology. 2018; 29(1): 36–43. https://doi.org/10.1093/annonc/mdx757

8. Bobrovskaya O.N. On the patient’s right for pain relief in palliative care. Medical law. 2019; 4(86): 36–40 (In Russian). EDN: QUSIJM

9. Ferrell B., Paice J., Koczywas M. New standards and implications for improving the quality of supportive oncology practice. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008; 26(23): 3824–3831. https://doi.org/10.1200/JCO.2007.15.7552

10. Larionova V.B., Snegovoy A.V. Possibilities of supportive therapy in patients with blood system tumors and malignant neoplasms. Oncohematology. 2020; 15(3): 107–127 (In Russian). https://doi.org/10.17650/1818-8346-2020-15-3-107-127. EDN: IHHBFF

11. Alderman B., Allan L., Amano K., et al. Multinational Association of Supportive Care in Cancer (MASCC) expert opinion/guidance on the use of clinically assisted nutrition in patients with advanced cancer. Support Care Cancer. 2022; 30(4): 2983–2992. https://doi.org/10.1007/s00520-021-06613-y

12. Popescu R.A., Roila F., Arends J., et al. Supportive Care: Low Cost, High Value. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2021; 41: 1–11. https://doi.org/10.1200/EDBK_320041

13. Miniotti M., Botto R., Soro G., et al. Critical Overview of the Construct of Supportive Care Need in the Cancer Literature: Definitions, Measures, Interventions and Future Directions for Research. Int J Environ Res Public Health. 2024; 21(2): 215. https://doi.org/10.3390/ijerph21020215

14. Snegovoy A.V., Larionova V.B., Kononenko I.B. Anorexia-cachexia syndrome in cancer patients: pathogenetic aspects and treatment options. Oncohematology. 2020; 15(4): 91–102 (In Russian) https://doi.org/10.17650/1818-8346-2020-15-4-91-102. EDN: NQPKDW

15. Reshetnikov A.V., Gevandova M.G., Prisyazhnaya N.V. Features of the legal and regulatory framework of rendering oncological assistance to children in Russia and abroad. Medical Bulletin of the North Caucasus. 2019; 14(2): 412–416 (In Russian). http://dx.doi.org/10.14300/mnnc.2019.14102. EDN: BWSMJV